← Back to guidelines
Cardiology59 papers

Capsular portal cirrhosis

Last edited: 4/15/2026

Overview

Capsular portal cirrhosis, often referred to in the context of breast implant complications, involves the formation of a thickened, contracted capsule around the implant, leading to firmness and potential dysfunction. This condition can also manifest in ocular contexts, such as capsular bag distention syndrome post-intraocular lens implantation, causing myopia and visual disturbances 2.

Diagnosis

  • Clinical Presentation: Presence of a thickened, contracted capsule around the implant, leading to firmness and potential pain or distortion 1.
  • Ocular Context: Postoperative myopia and changes in keratometric values, axial length, and anterior chamber depth 2.
  • Grading: Commonly assessed using Baker classification for breast implant complications (Grade I to IV) 13.
  • Management

  • First-Line Treatments:
  • - Submuscular Implant Replacement: For severe cases, repositioning implants submuscularly can lead to substantial improvement 3.
  • Pharmacological Interventions:
  • - Pirfenidone: Reduced capsule thickness, fibroblast proliferation, and inflammatory cell recruitment in animal models; dose 200 mg/kg daily 1.
  • Surgical Interventions:
  • - Capsulotomy/Capsulectomy: Direct surgical intervention to release or remove the contracted capsule 3.

    Special Populations

  • No Specific Data Provided: Abstracts do not cover management specifics for pregnancy, pediatrics, elderly, or comorbidities related to capsular portal cirrhosis.
  • Key Recommendations

  • Consider Submuscular Implant Placement for Severe Capsular Contracture: Repositioning implants submuscularly can significantly improve outcomes in severe cases (Evidence: Moderate 3).
  • Evaluate Use of Pirfenidone in Preventing Capsular Contracture: Utilize pirfenidone at 200 mg/kg daily to reduce fibrosis and inflammation in at-risk patients (Evidence: Weak 1).
  • Perform Capsulotomy or Capsulectomy for Symptomatic Cases: Surgical intervention is effective for managing symptomatic severe contractures (Evidence: Expert opinion 3).
  • References

    1 Gancedo M, Ruiz-Corro L, Salazar-Montes A, Rincón AR, Armendáriz-Borunda J. Pirfenidone prevents capsular contracture after mammary implantation. Aesthetic plastic surgery 2008. link 2 Sorenson AL, Holladay JT, Kim T, Kendall CJ, Carlson AN. Ultrasonographic measurement of induced myopia associated with capsular bag distention syndrome. Ophthalmology 2000. link00020-8) 3 Hoffman S. The management of severe capsular contractures following breast augmentation. Aesthetic plastic surgery 1983. link

    Original source

    1. [1]
      Pirfenidone prevents capsular contracture after mammary implantation.Gancedo M, Ruiz-Corro L, Salazar-Montes A, Rincón AR, Armendáriz-Borunda J Aesthetic plastic surgery (2008)
    2. [2]
      Ultrasonographic measurement of induced myopia associated with capsular bag distention syndrome.Sorenson AL, Holladay JT, Kim T, Kendall CJ, Carlson AN Ophthalmology (2000)
    3. [3]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG